Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

We need more policy leaders who are genuinely committed to challenging corporate power without harmful quackery.

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

From PBMs to abortion, there are plenty of health policy issues that will vie for the spotlight in 2025. For pharma marketers ...

Pharmaceutical companies are raising the price of over 250 brand drugs this year. Nearly all the price increases are under 10 ...

Everything from a new player-owned basketball league to a self-driving car service made headlines as the year wraps up.

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Stock market giants including Nvidia and Walmart completed stock splits in 2024. Investors like these operations because they ...